Adalimumab is a fully human monoclonal antibody targeted toward tumor necrosis 
factor alpha (TNF-alpha). TNF-alpha is proinflammatory cytokine involved in the 
pathogenesis of many inflammatory diseases, as the psoriasis. The production 
process of adalimumab is complex and it is based in the called phague display 
technology.